Clinical Pharmacology of Aliskiren in Combination With Cyclosporine in Cardiac Transplantation

Hypertension Clinical Trial

Official title:

Clinical Pharmacology of Aliskiren in Combination With Cyclosporine in Cardiac Transplantation

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01235910
• Other study ID #: 10-0746
• Status: Terminated
• Phase: Phase 4
• Start date: May 2011
• Est. completion date: December 2012

Study information

• Verified date: May 2018
• Source: University of Colorado, Denver
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and efficacy of the blood pressure medication, aliskiren, in heart transplant patients. In terms of safety, the investigators will evaluate the blood levels of aliskiren and determine if aliskiren alters the blood levels of the anti-rejection medication, cyclosporine, in these patients. In terms of efficacy, the investigators will determine how well aliskiren lowers blood pressure in heart transplant patients.

Description:

Hypertension is a major complication following cardiac transplantation, with a prevalence of 93% at 5 years post-transplant. Post-cardiac transplant hypertension is due to multiple factors such as use of cyclosporine, chronic kidney disease, and denervation. Hypertension in this population is difficult to treat, and most patients require therapy with multiple antihypertensive agents in order to achieve adequate blood pressure control. Aliskiren, a direct renin inhibitor, is a novel antihypertensive agent with a unique mechanism of action and potent blood pressure-lowering effects. As such, aliskiren is an attractive treatment option for post-cardiac transplant hypertension. This study will characterize the pharmacokinetic drug-drug interaction profile, pharmacodynamics, and safety of aliskiren 75 mg daily (low-dose) and 150 mg daily, when given in combination with cyclosporine, in cardiac transplant patients.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 1
• Est. completion date: December 2012
• Est. primary completion date: December 2012
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 70 Years

Eligibility

Inclusion Criteria:

• 6 months or more since cardiac transplant

• Clinically stable from a transplant perspective

• Maintained on a stable immunosuppressant regimen containing cyclosporine + an antiproliferative agent (e.g., azathioprine, mycophenolate), +/- an oral steroid

• Hypertension, as defined by a seated average systolic blood pressure of = 140 mm Hg and a seated average diastolic blood pressure of = 90 mm Hg, based on 3 separate measurements, spaced 2 minutes apart.

Exclusion Criteria:

• Clinical instability from a cardiac transplant perspective

• Contraindications to aliskiren therapy

• Conditions that may increase the risk of aliskiren adverse effects

• Severe hypertension

• Concomitant medications known to increase or decrease aliskiren plasma exposure.

Related Conditions & MeSH terms

• Cardiac Transplantation
• Hypertension

Intervention

Drug:
• Aliskiren
Aliskiren 75 mg once daily x 2 weeks, then aliskiren 150 mg once daily x 2 weeks, if blood pressure allows

Locations

Country	Name	City	State
United States	University of Colorado Denver	Aurora	Colorado

Sponsors (2)

Lead Sponsor	Collaborator
University of Colorado, Denver	American Heart Association

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose-normalized Cyclosporine Area Under the Plasma Concentration-time Curve (AUC)	The study was stopped due to difficulty finding patients who met the strict inclusion criteria. Only one patient was started on the study drug. as a result we did not analyze any cyclosporine PK (e.g.(AUCs) for this study.	7 days, 14 days, 30 days (End of Study)
Secondary	Aliskiren Plasma Concentrations	Maximum plasma concentration; area under the concentration-time curve, half-life, oral clearance; The study was stopped due to difficulty finding patients who met the strict inclusion criteria. Only one patient was started on the study drug. as a result we did not analyze any PK (e.g.(AUCs) for this study.	2 weeks
Secondary	Blood Pressure	The study was stopped due to difficulty finding patients who met the strict inclusion criteria. Only one patient was started on the study drug. as a result we did not analyze any blood pressure for this study.	2 weeks